{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Zhang W"],"pubmed_abstract":["<b>Objective:</b> Keluoxin capsule (KLXC) has been widely used in diabetic kidney disease (DKD), but its efficacy and safety have not yet been clarified. A systematic review and meta-analysis were performed to assess the efficacy and safety of KLXC for DKD. <b>Methods:</b> The randomized control trials (RCTs) included KLXC searched from seven major English and Chinese databases up until 3 June 2022. The methodological quality and risk of bias were assessed by version 2 of the Cochrane risk-of-bias tool (RoB 2) for the RCTs from the Cochrane Handbook. The analyses were conducted by RevMan 5.4 and Stata 17.0. <b>Results:</b> A total of 20 trials with 1,500 participants were identified. The meta-analysis showed that KLXC combined with Western medicine was superior to the use of Western medici"],"journal":["Frontiers in pharmacology"],"pagination":["1052852"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9845565"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of Keluoxin capsule in combination with Western medicine for diabetic kidney disease: A systematic review and meta-analysis."],"pmcid":["PMC9845565"],"pubmed_authors":["Zhang W","Jiang Y","Wang C","Jia W","Wang X","Zhang S","Lin L","Gong Y","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of Keluoxin capsule in combination with Western medicine for diabetic kidney disease: A systematic review and meta-analysis.","description":"<b>Objective:</b> Keluoxin capsule (KLXC) has been widely used in diabetic kidney disease (DKD), but its efficacy and safety have not yet been clarified. A systematic review and meta-analysis were performed to assess the efficacy and safety of KLXC for DKD. <b>Methods:</b> The randomized control trials (RCTs) included KLXC searched from seven major English and Chinese databases up until 3 June 2022. The methodological quality and risk of bias were assessed by version 2 of the Cochrane risk-of-bias tool (RoB 2) for the RCTs from the Cochrane Handbook. The analyses were conducted by RevMan 5.4 and Stata 17.0. <b>Results:</b> A total of 20 trials with 1,500 participants were identified. The meta-analysis showed that KLXC combined with Western medicine was superior to the use of Western medici","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T13:53:24.093Z","creation":"2025-04-04T13:53:24.093Z"},"accession":"S-EPMC9845565","cross_references":{"pubmed":["36686708"],"doi":["10.3389/fphar.2022.1052852"]}}